Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland
Crossref DOI link: https://doi.org/10.1186/s12890-018-0610-z
Published Online: 2018-03-16
Published Print: 2018-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jahnz-Różyk, Karina
Lis, Joanna
Warchoł, Marta
Kucharczyk, Aleksandra http://orcid.org/0000-0003-2804-0226